There are also evidences demonstrated that the elimination of exosomes by inhibiting generation and secretion or extracorporeal hemofiltration may act as an effective add-on therapy to enhance the efficiency of anti-PD-1/PD-L1 therapy [180, 182, 183], which may provide new clinical application prospects for cancer treatment in future [184]. This evidence concerns the gene PDCD1 and cancer.